Silber S, Tofte A J, Kjellevand T O, Grube E, Gershony G
Dr. Müller Hospital, Munich, Germany.
Herz. 1999 Dec;24(8):620-3. doi: 10.1007/BF03044486.
Duett, a novel vascular sealing device, was first clinically used in July 1997. A European multi-center registry was established to evaluate the safety and procedural success of the Duett sealing device in a broad range of patients undergoing diagnostic or interventional endovascular procedures. At 25 European sites 1587 patients were enrolled. All patients (> or = 18 years) must have given informed consent for the use of the sealing device after a diagnostic and/or interventional endovascular procedure performed via a femoral arterial approach. Standard length (< or = 10 cm) 5 to 9 F introducer sheaths had to be used. An ACT of < or = 400 s, and any approved GP IIb/IIIa platelet receptor antagonist was permitted. Successful deployment could be achieved in 96.2% (1526/1587 patients) with complete hemostasis within 2 to 5 minutes in over 95% of the patients. The complication-free rate was 96.4%. Arterial occlusions were rare (4 patients) and successfully treated with surgical repair in 1 and with thrombolysis in 3 patients. Pseudoaneurysms occurred in 34 patients, the majority (30/34) were successfully treated with ultrasound-guided compression or resolved spontaneously. The total rate of major complications was 2.6% (41/1587). The final results of the European registry demonstrate that the Duett sealing device can be used with a high procedural success following diagnostic and interventional endovascular procedures. The incidence of major complications is low and comparable to all other approved vascular closure devices and manual compression. CE-mark certification was approved at the end of 1998.
Duett是一种新型血管封堵装置,于1997年7月首次应用于临床。欧洲建立了一个多中心注册研究,以评估Duett封堵装置在接受诊断性或介入性血管内手术的广泛患者中的安全性和手术成功率。在欧洲的25个中心招募了1587例患者。所有患者(≥18岁)在经股动脉途径进行诊断性和/或介入性血管内手术后,必须已签署使用封堵装置的知情同意书。必须使用标准长度(≤10 cm)的5至9F导入鞘。激活凝血时间(ACT)≤400秒,允许使用任何已获批准的GP IIb/IIIa血小板受体拮抗剂。96.2%(1526/1587例患者)实现了成功置入,超过95%的患者在2至5分钟内实现了完全止血。无并发症发生率为96.4%。动脉闭塞很少见(4例患者),1例通过手术修复成功治疗,3例通过溶栓成功治疗。34例患者发生假性动脉瘤,大多数(30/34)通过超声引导压迫成功治疗或自行消退。主要并发症的总发生率为2.6%(41/1587)。欧洲注册研究的最终结果表明,Duett封堵装置在诊断性和介入性血管内手术后使用时手术成功率很高。主要并发症的发生率很低,与所有其他已获批准的血管闭合装置和手动压迫相当。1998年底获得了CE标志认证。